Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.43 |
| ▸ | MAOB | P27338 | 8/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17024108 | 0.86 | CYP3A4 (0.56) | MAPTHRH3HTTHIF1AAR | |
| SCHEMBL17024101 | 0.85 | MAPT (0.50) | NPC1MAPTRAB9AMAOBHTT | |
| SCHEMBL28000798 | 0.82 | LMNA (0.55) | NPC1MAPTRAB9ARECQLHRH3 | |
| SCHEMBL31098426 | 0.81 | RECQL (0.52) | NPC1MAPTRAB9ARECQLHRH3 | |
| SCHEMBL17024104 | 0.80 | KMT2A (0.55) | HTTHIF1AARTDP1 | |
| SCHEMBL15677149 | 0.79 | AR (0.64) | NPC1MAPTRAB9ARECQLHTT | |
| SCHEMBL17024121 | 0.77 | ALDH1A1 (0.44) | NPC1MAPTRAB9AMAOBHTT | |
| SCHEMBL14388778 | 0.74 | NPC1 (0.47) | NPC1MAPTRAB9ARECQLHRH3 | |
| SCHEMBL8590307 | 0.74 | NPC1 (0.47) | NPC1MAPTRAB9ARECQLHRH3 | |
| SCHEMBL5327538 | 0.74 | NPC1 (0.47) | NPC1MAPTRAB9ARECQLHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915796-A1 | PROPYL-PHENYL-ETHER DERIVATIVE AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT, AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150238401-A1 | PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE | SEIWA KASEI COMPANY, LIMITED (JP) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238401-A1 | PROPYL-PHENYL-ETHER DERIVATIVE, AND MELANOGENESIS INHIBITOR, SKIN-LIGHTENING AGENT, ANTIMICROBIAL AGENT AND COSMETIC CONTAINING SAID PROPYL-PHENYL-ETHER DERIVATIVE | TYR, MITF, MC1R | NPC1 3942/4885MAPT 1564/4885RAB9A 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.